期刊： BLOOD CANCER DISCOVERY, 2022; 3 (4)
Approximately 20% of patients with myeloproliferative neoplasms (MPN) harbor mutations in the gene calreticulin (CALR), with 80% of those mutations cl......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (1)
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to defi ......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (4)
Progression from myelodysplastic syndromes (MDS) to secondary acute myeloid leukemia (AML) is associated with the acquisition and expansion of subclon......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (5)
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microen-vironment that is rich in nonmalignant immune cells. We applied single-ce......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (1)
Diffuse large B-cell lymphomas (DLBCL) are broadly dependent on anaplerotic metabolism regulated by mitochondrial SIRT3. Herein we fi nd that translat......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (5)
To explore the role of clonal hematopoiesis (CH) in chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep sequencing on ......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (5)
Relapse of acute myeloid leukemia (AML) after allogeneic bone marrow transplantation has been linked to immune evasion due to reduced expression of ma......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (6)
Myeloblast expansion is a hallmark of disease progression and comprises CD34+ hematopoietic stem and progenitor cells (HSPC). How this compartment evo......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (6)
SF3B1 mutations, which occur in 20% of patients with myelodysplastic syndromes (MDS), are the hallmarks of a specifi c MDS subtype, MDS with ringed si......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (3)
In this issue of Blood Cancer Discovery, Wintersinger and colleagues present a new algorithm for quickly and accurately inferring clonal phylogenies f......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (1)
Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes even within pathologic diagnoses. Treatment response assessme......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (2)
Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CR5 refract......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (3)
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively d......
期刊： BLOOD CANCER DISCOVERY, 2022; 3 (6)
Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging d......
